No Data
Stifel Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Cuts Target Price to $16
Express News | Black Diamond Therapeutics Inc : Stifel Cuts Target Price to $16 From $18
Black Diamond Therapeutic Analyst Ratings
TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating
Strong Buy Rating for Black Diamond Therapeutics Driven by Financial Stability and Promising Clinical Developments
Express News | Black Diamond Therapeutics Inc: Clinical Updates of Bdtx-1535 in Egfrm Nsclc and Regulatory Feedback Expected in Q1 2025
NYC-yolo OP : I am a divine prophecy.